There are no Transcripts on CRT.
Wed, Apr. 2, 7:59 AM
- Boston Scientific (BSX) has reported favorable results in almost a dozen studies that tested the company's cardiac resynchronization therapy (CRT) defibrillators, platinum chromium stent platforms, and transcatheter aortic valve replacement.
- Boston Scientific presented the data at the American College of Cardiology's Annual Scientific Session.
- In a long-term study of patients with mild heart failure, there was a 41% relative reduction in the risk of death in those who received a Boston Scientific defibrillator with CRT compared with patients who received just a defibrillator. (PR)
CRT vs. ETF Alternatives
Other News & PR